MINK THERAPEUTICS INC

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

08 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

04 Oct 2024 09:10:00 By Nasdaq GlobeNewswire

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

03 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Reports Second Quarter 2024 Results and Business Update

13 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

31 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

05 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

22 May 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Reports First Quarter 2024 Results

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

13 May 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

30 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

08 Apr 2024 12:00:00 By Nasdaq GlobeNewswire

MiNK Reports Fourth Quarter and Year-End 2023 Results

21 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

07 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

14 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

06 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

30 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

20 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

MiNK Therapeutics Reports Third Quarter 2023 Results

09 Nov 2023 07:00:01 By Nasdaq GlobeNewswire